Tellez D W, Galvis A G, Storgion S A, Amer H N, Hoseyni M, Deakers T W
Division of Pediatric Intensive Care, Childrens Hospital Los Angeles, CA 90027.
J Pediatr. 1991 Feb;118(2):289-94. doi: 10.1016/s0022-3476(05)80505-0.
To assess whether there is any advantage in the use of corticosteroid to prevent postextubation stridor in children, we conducted a prospective, randomized, double-blind trial of dexamethasone versus saline solution. The patients were evaluated and then randomly selected to receive either dexamethasone or saline solution according to a stratification based on risk factors for postextubation stridor: age, duration of intubation, upper airway trauma, circulatory compromise, and tracheitis. Dexamethasone, 0.5 mg/kg, was given every 6 hours for a total of six doses beginning 6 to 12 hours before and continuing after endotracheal extubation in a pediatric intensive care setting. There was no statistical difference in incidence of postextubation stridor in the two groups; 23 of 77 children in the placebo group and 16 of 76 in the dexamethasone group had stridor requiring therapy (p = 0.21). We conclude that the routine use of corticosteroids for the prevention of postextubation stridor during uncomplicated pediatric intensive care airway management is unwarranted.
为评估使用皮质类固醇预防儿童拔管后喘鸣是否有任何优势,我们进行了一项地塞米松与生理盐水对比的前瞻性、随机、双盲试验。根据拔管后喘鸣的危险因素(年龄、插管时间、上呼吸道创伤、循环功能不全和气管炎)进行分层,对患者进行评估,然后随机选择接受地塞米松或生理盐水。在儿科重症监护环境中,于气管插管前6至12小时开始,每6小时给予地塞米松0.5mg/kg,共六剂,气管插管后继续给药。两组拔管后喘鸣的发生率无统计学差异;安慰剂组77名儿童中有23名、地塞米松组76名中有16名出现需要治疗的喘鸣(p = 0.21)。我们得出结论,在无并发症的儿科重症监护气道管理中,常规使用皮质类固醇预防拔管后喘鸣是不必要的。